NRP2 and lobular breast carcinoma in situ: Additionally, further research efforts are needed to demonstrate that SEMA3F, NRP1 and NRP2 could work as risk progression markers not only for DCIS, but also for the other pre-invasive lesion in BC, lobular carcinoma in situ (LCIS), and especially for those that are submitted to treatment, the pleomorphic LCIS [96].